Class I Histone Deacetylase Inhibition by Tianeptinaline Modulates Neuroplasticity and Enhances Memory
Open accessThe DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abstract
Through epigenetic and other regulatory functions, the histone deacetylase (HDAC) family of enzymes has emerged as a promising therapeutic target for central nervous system and other disorders. Here we report on the synthesis and functional characterization of new HDAC inhibitors based structurally on tianeptine, a drug used primarily to treat major depressive disorder (MDD) that has a poorly understood mechanism of action. Since the chemical structure of tianeptine resembles certain HDAC inhibitors, we profiled the in vitro HDAC inhibitory activity of tianeptine and demonstrated its ability to inhibit the lysine deacetylase activity of a subset of class I HDACs. Consistent with a model of active site Zn 2+ chelation by the carboxylic acid present in tianeptine, newly synthesized analogues containing either a hydroxamic acid or ortho -aminoanilide exhibited increased potency and selectivity among the HDAC family. This in vitro potency translated to improved efficacy in a panel of high-content imaging assays designed to assess HDAC target engagement and functional effects on critical pathways involved in neuroplasticity in both primary mouse neurons and, for the first time, human neurons differentiated from pluripotent stem cells. Most notably, tianeptinaline, a class I HDAC-selective analogue of tianeptine, but not tianeptine itself, increased histone acetylation, and enhanced CREB-mediated transcription and the expression of Arc (activity-regulated cytoskeleton-associated protein). Systemic in vivo administration of tianeptinaline to mice confirmed its brain penetration and was found to enhance contextual fear conditioning, a behavioral test of hippocampal-dependent memory. Tianeptinaline and its derivatives provide new pharmacological tools to dissect chromatin-mediated neuroplasticity underlying memory and other epigenetically related processes implicated in health and disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“While most HDACi tend to employ a hydroxamic acid as a ZBG, class I HDACs (particularly HDACs 1–3) tend to be the only class of HDACs inhibited by 2-amino anilides as a ZBG (Figure 4A) [9–13].”
From Medicinal chemistry advances in targeting class I histone deacetylases (2023) · cites this paper as [9]
In the citing paper
“For this reason, RGFP966 (Figure 11) has emerged as the most frequently employed tool for HDAC3 pharmacologic inhibition in biological studies [9, 13, 67, 69–71].”
From Medicinal chemistry advances in targeting class I histone deacetylases (2023) · cites this paper as [9]
Citations
Cites
Integrative analysis of 111 reference human epigenomes
Roadmap Epigenomics Consortium, Kundaje, A., Meuleman, W., Ernst, J., Bilenky, M., Yen, A., Heravi-Moussavi, A., Kheradpour, P., Zhang, Z., Wang, J., et al. (2015) · Nature · doi:10.1038/nature14248 · Cited by 6,368
Self-citationStructures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors
Finnin, M. S., Donigian, J. R., Cohen, A., Richon, V. M., Rifkind, R. A., Marks, P. A., Breslow, R., & Pavletich, N. P. (1999) · Nature · doi:10.1038/43710 · Cited by 1,714
HDAC2 negatively regulates memory formation and synaptic plasticity
Guan, J.-S., Haggarty, S. J., Giacometti, E., Dannenberg, J.-H., Joseph, N., Gao, J., Nieland, T. J. F., Zhou, Y., Wang, X., Mazitschek, R., et al. (2009) · Nature · doi:10.1038/nature07925 · Cited by 1,644
Self-citationSilva, A. J., Kogan, J. H., Frankland, P. W., & Kida, S. (1998) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.21.1.127 · Cited by 1,462
Recovery of learning and memory is associated with chromatin remodelling
Fischer, A., Sananbenesi, F., Wang, X., Dobbin, M., & Tsai, L.-H. (2007) · Nature · doi:10.1038/nature05772 · Cited by 1,227
Self-citationAltered Histone Acetylation Is Associated with Age-Dependent Memory Impairment in Mice
Peleg, S., Sananbenesi, F., Zovoilis, A., Burkhardt, S., Bahari-Javan, S., Agis-Balboa, R. C., Cota, P., Wittnam, J. L., Gogol-Doering, A., Opitz, L., et al. (2010) · Science · doi:10.1126/science.1186088 · Cited by 951
An epigenetic blockade of cognitive functions in the neurodegenerating brain
Gräff, J., Rei, D., Guan, J.-S., Wang, W.-Y., Seo, J., Hennig, K. M., Nieland, T. J. F., Fass, D. M., Kao, P. F., Kahn, M., et al. (2012) · Nature · doi:10.1038/nature10849 · Cited by 853
Self-citationChemical phylogenetics of histone deacetylases
Bradner, J. E., West, N., Grachan, M. L., Greenberg, E. F., Haggarty, S. J., Warnow, T., & Mazitschek, R. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.313 · Cited by 720
Self-citationChemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes
Bantscheff, M., Hopf, C., Savitski, M. M., Dittmann, A., Grandi, P., Michon, A.-M., Schlegl, J., Abraham, Y., Becher, I., Bergamini, G., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1759 · Cited by 659
Vannini, A., Volpari, C., Filocamo, G., Casavola, E. C., Brunetti, M., Renzoni, D., Chakravarty, P., Paolini, C., De Francesco, R., Gallinari, P., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404603101 · Cited by 638
New Insights in the Biology of BDNF Synthesis and Release: Implications in CNS Function
Greenberg, M. E., Xu, B., Lu, B., & Hempstead, B. L. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.3566-09.2009 · Cited by 597
Sakamoto, K., Karelina, K., & Obrietan, K. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.07080.x · Cited by 543
HDAC3 Is a Critical Negative Regulator of Long-Term Memory Formation
McQuown, S. C., Barrett, R. M., Matheos, D. P., Post, R. J., Rogge, G. A., Alenghat, T., Mullican, S. E., Jones, S., Rusche, J. R., Lazar, M. A., et al. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.5052-10.2011 · Cited by 507
Bramham, C. R., Alme, M. N., Bittins, M., Kuipers, S. D., Nair, R. R., Pai, B., Panja, D., Schubert, M., Soule, J., Tiron, A., et al. (2010) · Experimental Brain Research · doi:10.1007/s00221-009-1959-2 · Cited by 452
CREB's control of intrinsic and synaptic plasticity: implications for CREB-dependent memory models
Benito, E., & Barco, A. (2010) · Trends in Neurosciences · doi:10.1016/j.tins.2010.02.001 · Cited by 448
Lauffer, B. E. L., Mintzer, R., Fong, R., Mukund, S., Tam, C., Zilberleyb, I., Flicke, B., Ritscher, A., Fedorowicz, G., Vallero, R., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.490706 · Cited by 429
HDAC3-selective inhibitor enhances extinction of cocaine-seeking behavior in a persistent manner
Malvaez, M., McQuown, S. C., Rogge, G. A., Astarabadi, M., Jacques, V., Carreiro, S., Rusche, J. R., & Wood, M. A. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1213364110 · Cited by 395
Tianeptine: A Review of its Use in Depressive Disorders
Wagstaff, A. J., Ormrod, D., & Spencer, C. M. (2001) · CNS Drugs · doi:10.2165/00023210-200115030-00006 · Cited by 394
Arc in synaptic plasticity: from gene to behavior
Korb, E., & Finkbeiner, S. (2011) · Trends in Neurosciences · doi:10.1016/j.tins.2011.08.007 · Cited by 388
Isoform-selective histone deacetylase inhibitors
Bieliauskas, A. V., & Pflum, M. K. H. (2008) · Chemical Society Reviews · doi:10.1039/b703830p · Cited by 350
Sheridan, S. D., Theriault, K. M., Reis, S. A., Zhou, F., Madison, J. M., Daheron, L., Loring, J. F., & Haggarty, S. J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026203 · Cited by 317
Self-citationThe Potential of HDAC Inhibitors as Cognitive Enhancers
Gräff, J., & Tsai, L.-H. (2013) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011112-140216 · Cited by 298
Self-citationThe Behavioral Effects of the Antidepressant Tianeptine Require the Mu-Opioid Receptor
Samuels, B. A., Nautiyal, K. M., Kruegel, A. C., Levinstein, M. R., Magalong, V. M., Gassaway, M. M., Grinnell, S. G., Han, J., Ansonoff, M. A., Pintar, J. E., et al. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.60 · Cited by 274
Catalysis and substrate selection by histone/protein lysine acetyltransferases
Berndsen, C. E., & Denu, J. M. (2008) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2008.11.004 · Cited by 227
Pimelic Diphenylamide 106 Is a Slow, Tight-binding Inhibitor of Class I Histone Deacetylases
Chou, C. J., Herman, D., & Gottesfeld, J. M. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m807045200 · Cited by 223
The atypical antidepressant and neurorestorative agent tianeptine is a μ-opioid receptor agonist
Gassaway, M. M., Rives, M.-L., Kruegel, A. C., Javitch, J. A., & Sames, D. (2014) · Translational Psychiatry · doi:10.1038/tp.2014.30 · Cited by 195
Methot, J. L., Chakravarty, P. K., Chenard, M., Close, J., Cruz, J. C., Dahlberg, W. K., Fleming, J., Hamblett, C. L., Hamill, J. E., Harrington, P., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.12.031 · Cited by 191
Targeting Class I Histone Deacetylases in a “Complex” Environment
Millard, C. J., Watson, P. J., Fairall, L., & Schwabe, J. W. R. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.12.006 · Cited by 180
Moradei, O. M., Mallais, T. C., Frechette, S., Paquin, I., Tessier, P. E., Leit, S. M., Fournel, M., Bonfils, C., Trachy-Bourget, M.-C., Liu, J., et al. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm701079h · Cited by 166
Schroeder, F. A., Lewis, M. C., Fass, D. M., Wagner, F. F., Zhang, Y.-L., Hennig, K. M., Gale, J., Zhao, W.-N., Reis, S., Barker, D. D., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071323 · Cited by 146
Self-citationDeacetylase Activity Is Required for cAMP Activation of a Subset of CREB Target Genes
Fass, D. M., Butler, J. E. F., & Goodman, R. H. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m305905200 · Cited by 137
Self-citationChronic Oral Administration of CI-994: A Phase I Study
Prakash, S., Foster, B. J., Meyer, M., Wozniak, A., Heilbrun, L. K., Flaherty, L. E., Zalupski, M. M., Radulovic, L. L., Valdivieso, M., & LoRusso, P. M. (2001) · Investigational New Drugs · doi:10.1023/a:1006489328324 · Cited by 136
Tuning acetylation levels with HAT activators: Therapeutic strategy in neurodegenerative diseases
Selvi, B. R., Cassel, J., Kundu, T. K., & Boutillier, A. (2010) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2010.08.012 · Cited by 130
Wilde, M. I., & Benfield, P. (1995) · Drugs · doi:10.2165/00003495-199549030-00007 · Cited by 129
Emerging Roles of CREB-Regulated Transcription Coactivators in Brain Physiology and Pathology
Saura, C. A., & Cardinaux, J. (2017) · Trends in Neurosciences · doi:10.1016/j.tins.2017.10.002 · Cited by 119
Small Molecule Inhibitors of Zinc-dependent Histone Deacetylases
Wagner, F. F., Weïwer, M., Lewis, M. C., & Holson, E. B. (2013) · Neurotherapeutics · doi:10.1007/s13311-013-0226-1 · Cited by 107
Insights into neuroepigenetics through human histone deacetylase PET imaging
Wey, H.-Y., Gilbert, T. M., Zürcher, N. R., She, A., Bhanot, A., Taillon, B. D., Schroeder, F. A., Wang, C., Haggarty, S. J., & Hooker, J. M. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf7551 · Cited by 107
Self-citationFass, D. M., Reis, S. A., Ghosh, B., Hennig, K. M., Joseph, N. F., Zhao, W.-N., Nieland, T. J. F., Guan, J.-S., Groves Kuhnle, C. E., Tang, W., et al. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.06.043 · Cited by 105
Self-citationSilva, M. C., Cheng, C., Mair, W., Almeida, S., Fong, H., Biswas, M. H. U., Zhang, Z., Huang, Y., Temple, S., Coppola, G., et al. (2016) · Stem Cell Reports · doi:10.1016/j.stemcr.2016.08.001 · Cited by 103
Self-citationProbing the role of HDACs and mechanisms of chromatin-mediated neuroplasticity
Haggarty, S. J., & Tsai, L.-H. (2011) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2011.04.009 · Cited by 100
Self-citationOptimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2)
Witter, D. J., Harrington, P., Wilson, K. J., Chenard, M., Fleming, J. C., Haines, B., Kral, A. M., Secrist, J. P., & Miller, T. A. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.11.047 · Cited by 93
Short-Chain HDAC Inhibitors Differentially Affect Vertebrate Development and Neuronal Chromatin
Fass, D. M., Shah, R., Ghosh, B., Hennig, K., Norton, S., Zhao, W.-N., Reis, S. A., Klein, P. S., Mazitschek, R., Maglathlin, R. L., et al. (2011) · ACS Medicinal Chemistry Letters · doi:10.1021/ml1001954 · Cited by 89
Self-citationWagner, F. F., Lundh, M., Kaya, T., McCarren, P., Zhang, Y.-L., Chattopadhyay, S., Gale, J. P., Galbo, T., Fisher, S. L., Meier, B. C., et al. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.5b00640 · Cited by 86
Wagner, F. F., Weïwer, M., Steinbacher, S., Schomburg, A., Reinemer, P., Gale, J. P., Campbell, A. J., Fisher, S. L., Zhao, W., Reis, S. A., et al. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.06.040 · Cited by 79
Self-citationEpigenetic Mechanisms in Psychiatry
Nestler, E. J. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.10.030 · Cited by 78
Selective HDAC Inhibition for the Disruption of Latent HIV-1 Infection
Barton, K. M., Archin, N. M., Keedy, K. S., Espeseth, A. S., Zhang, Y.-L., Gale, J., Wagner, F. F., Holson, E. B., & Margolis, D. M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0102684 · Cited by 76
Alam†, M. S., Getz, M., & Haldar, K. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad9407 · Cited by 72
Bieszczad, K. M., Bechay, K., Rusche, J. R., Jacques, V., Kudugunti, S., Miao, W., Weinberger, N. M., McGaugh, J. L., & Wood, M. A. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.0914-15.2015 · Cited by 71
Epigenetic mechanisms in mood disorders: Targeting neuroplasticity
Fass, D. M., Schroeder, F. A., Perlis, R. H., & Haggarty, S. J. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2013.01.041 · Cited by 62
Self-citationBecher, I., Dittmann, A., Savitski, M. M., Hopf, C., Drewes, G., & Bantscheff, M. (2014) · ACS Chemical Biology · doi:10.1021/cb500235n · Cited by 60
A role for the mu opioid receptor in the antidepressant effects of buprenorphine
Robinson, S. A., Erickson, R. L., Browne, C. A., & Lucki, I. (2017) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.10.050 · Cited by 58
She, A., Kurtser, I., Reis, S. A., Hennig, K., Lai, J., Lang, A., Zhao, W.-N., Mazitschek, R., Dickerson, B. C., Herz, J., et al. (2017) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.06.010 · Cited by 50
Self-citationTranslating HDAC inhibitors in Friedreich’s ataxia
Soragni, E., & Gottesfeld, J. M. (2016) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2016.1215910 · Cited by 49
Neurochemical and Pharmacological Properties of Tianeptine, A Novel Antidepressant
Labrid, C., Mocaër, E., & Kamoun, A. (1992) · British Journal of Psychiatry · doi:10.1192/s0007125000296694 · Cited by 44
Tianeptine: An Antidepressant with Memory-Protective Properties
Zoladz, P., Park, C., Munoz, C., Fleshner, M., & Diamond, D. (2008) · Current Neuropharmacology · doi:10.2174/157015908787386096 · Cited by 41
Ghosh, B., Zhao, W., Reis, S. A., Patnaik, D., Fass, D. M., Tsai, L., Mazitschek, R., & Haggarty, S. J. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.01.022 · Cited by 38
Self-citationClinical Safety and Efficacy of Tianeptine in 1,858 Depressed Patients Treated in General Practice
Guelfi, J., Dulcire, C., Lemoine, P., & Tafani, A. (2008) · Neuropsychobiology · doi:10.1159/000118824 · Cited by 26
Chemogenomic analysis reveals key role for lysine acetylation in regulating Arc stability
Lalonde, J., Reis, S. A., Sivakumaran, S., Holland, C. S., Wesseling, H., Sauld, J. F. K., Alural, B., Zhao, W., Steen, J. A. J., & Haggarty, S. J. (2017) · Nature Communications · doi:10.1038/s41467-017-01750-7 · Cited by 23
Self-citationPharmacokinetics of the Antidepressant Tianeptine at Steady State in the Elderly
Demotes‐Mainard, F., Galley, P., Manciet, G., Vinson, G., & Salvadori, C. (1991) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1991.tb03703.x · Cited by 22
Epigenetic Regulation in the Nervous System
(2013) · Elsevier eBooks · doi:10.1016/c2011-0-06152-5 · Cited by 14
Bulaceanu-MacNair, M., Aaron, J., Prognon, P., & Mahuzier, G. (1998) · The Analyst · doi:10.1039/a804285c · Cited by 10
[Tolerability of tianeptine in 170 patients with depression treated during one year].
Löo, H., Ganry, H., Marey, C., Briole, G., Castelnau, D., Jf, C., Jm, D., Danion, J., DARCOURT, G., & Capdeville, C. (1990) · PubMed · Cited by 4
Research works printed but not linked: 1
- Loo H., 1990, Encephale, 16, 445
Cited by
Biomarkers in Psychiatry: Concept, Definition, Types and Relevance to the Clinical Reality
García-Gutiérrez, M. S., Navarrete, F., Sala, F., Gasparyan, A., Austrich-Olivares, A., & Manzanares, J. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00432 · Cited by 331
“More interestingly, histone deacetylases (HDAC), that have been demonstrated to control epigenetic programming associated with the modulation of behaviour and cognition, appears to be crucial for reversing dysfunctional epigenetic regulation induced by early life events exposure in preclinical models (109, 110).”
BackgroundStrategies To Design Selective Histone Deacetylase Inhibitors
Melesina, J., Simoben, C. V., Praetorius, L., Bülbül, E. F., Robaa, D., & Sippl, W. (2021) · ChemMedChem · doi:10.1002/cmdc.202000934 · Cited by 118
Rodrigues, D. A., Pinheiro, P. D. S. M., Sagrillo, F. S., Bolognesi, M. L., & Fraga, C. A. M. (2020) · Medicinal Research Reviews · doi:10.1002/med.21701 · Cited by 70
Cognitive epigenetic priming: leveraging histone acetylation for memory amelioration
Burns, A. M., & Gräff, J. (2021) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2020.08.011 · Cited by 62
Current trends in development of HDAC-based chemotherapeutics
Cheshmazar, N., Hamzeh‐Mivehroud, M., Charoudeh, H. N., Hemmati, S., Melesina, J., & Dastmalchi, S. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120946 · Cited by 60
Metadata
- Authors
- Zhao, W.-N., Ghosh, B., Tyler, M., Lalonde, J., Joseph, N. F., Kosaric, N., Fass, D. M., Tsai, L.-H., Mazitschek, R., & Haggarty, S. J.
- Affiliations
- Harvard University (US)
- Massachusetts Institute of Technology (US)
- Massachusetts General Hospital (US)
- Corresponding author
- Haggarty, Stephen J.
- ORCID
- Venue
- ACS Chemical Neuroscience
- Publisher
- American Chemical Society (ACS)
- Published
- 2018-06-22
- Volume
- 9
- Issue
- 9
- Pages
- 2262-2273
- ISSN
- 1948-7193 (ISSN-L)
- OpenAlex
- W2808733316
- Cited by
- 35
- References
- 62
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 3 · 2023: 2 · 2022: 7 · 2021: 7 · 2020: 5 · 2019: 3
- FWCI
- 1.33
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- cc-by-nc
- Locations
- ACS Chemical Neuroscience (publishedVersion)
- PubMed (publishedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc)
- Funders
- National Cancer Institute (P50CA086355)
- Massachusetts General Hospital
- National Institute on Drug Abuse (R01DA028301, R01DA030321)
- Bluefield Project to Cure Frontotemporal Dementia
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- tianeptine, class I histone deacetylase inhibitors, histone deacetylase inhibitors, neuroplasticity, memory enhancement, hippocampal-dependent memory, contextual fear conditioning, Arc expression, histone acetylation, epigenetics, brain penetration, major depressive disorder
- MeSH terms
- Animals, Conditioning, Psychological, Cytoskeletal Proteins, Fear, Histone Deacetylases, Humans, Memory, Nerve Tissue Proteins, Neuronal Plasticity, Neurons, Thiazepines, Transcription, Genetic, Cyclic AMP Response Element-Binding Protein, Pluripotent Stem Cells, Epigenesis, Genetic, Mice, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.